Diabetes Mellitus Interagency Collaborating Committee (DMICC) Type 1 Diabetes and Cardiorenal Outcomes: Informing a Practice Changing Trial

Event Details

Background

Cardiorenal disease, which includes cardiovascular and renal (i.e., kidney) disease, remains the leading cause of morbidity and mortality in individuals with Type 1 diabetes (T1D). While T1D impacts over 2.1 million people in the U.S., including approximately 314,000 children and adolescents, substantive evidence gaps remain in its pathophysiology (including differences with Type 2 diabetes) and the appropriate strategies to prevent and manage cardiorenal disease in these individuals. Over the past year, a panel of diabetes, cardiovascular, and renal experts has discussed the existing gaps and opportunities in T1D cardiorenal research and will present perspectives for a T1D specific cardiorenal trial with the potential to inform clinical guidelines and change standards of care.

About the Diabetes Mellitus Interagency Coordinating Committee (DMICC)

Chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the DMICC comprises representatives from across the Department of Health and Human Services (HHS) and other federal agencies supporting diabetes-related activities. The DMICC’s primary mission is to facilitate seamless cooperation, communication, and collaboration on diabetes initiatives across these government entities.

Meeting Objectives

This DMICC meeting serves as a forum for the expert diabetes and cardiorenal panel to present perspectives on a potential clinical trial design. These insights will inform future programmatic decisions by the NIDDK and the National Heart, Lung, and Blood Institute (NHLBI) aimed at reducing cardiorenal disease in individuals living with T1D. Members of the broader diabetes, cardiovascular, and renal research communities are strongly encouraged to attend and contribute their critical expertise.

Organizing Committee

William Cefalu, M.D.
Director, Division of Diabetes, Endocrinology and Metabolic Diseases (DEM), NIDDK 

Gina Wei, M.D., M.P.H.
On Detail to the Immediate Office of the Director (IOD), NHLBI 

Teresa Jones, M.D.
Program Director, DEM, NIDDK

Beena Akolkar, Ph.D.
Program Director, DEM, NIDDK

Nishadi Rajapakse, Ph.D., M.H.S.
Program Director, DEM, NIDDK

Nicole Redmond, M.D., Ph.D., M.P.H.
Acting Associate Director, Division of Cardiovascular Science (DCVS), NHLBI

Lawrence Fine, M.D., Ph.D., M.P.H.
Senior Advisor, IOD and Clinical Applications Branch, DCVS, NHLBI

Sarah Neser, D.N.P.
Clinical Trials Specialist/Program Analyst, NIDDK

Registration Deadline

September 11, 2026

Agenda

To be added when available

Travel

Hotel Accommodations

Hyatt Regency Bethesda
One Bethesda Metro Center
7400 Wisconsin Avenue
Bethesda, Maryland 20814
Telephone: (301) 657-1234
Website
Reservations
Cut-off date: Thursday, August 27, 2026

Government Room Rate

A limited block of sleeping rooms for meeting participants has been reserved at the Hyatt Regency Bethesda. The rate is $249 per night for single occupancy, plus tax (13%). The room block will be in effect until Thursday, August 27, 2026, or until full, whichever comes first. Any room reservations received after this date will be accepted on a space- and rate-availability basis. Please be certain that the hotel provides you with a confirmation number for your reservation.

Reservation Dates

Book your arrival date as Thursday, September 17, 2026, and departure as late as Saturday, September 19, 2026. If you require alternate dates, please contact Danielle Johnikin of The Scientific Consulting Group, Inc. (SCG).

Check-in and Checkout

Check-in time is 4:00 p.m., and checkout time is 12:00 p.m.

Cancellations

Failure to cancel your reservation in accordance with the hotel’s cancellation policy will result in a no-show fee of one night’s guest room rate plus tax on your credit card.